Better-than-expected. JPMorgan Chase reported today that quarterly earnings were well above Wall Street's expectations as trading revenues exceeded its own expectations on the back of a rebound in financial markets. Citigroup also published better-than-expected results, with quarterly net banking income and earnings higher than the Refinitiv IBES consensus.
URW reduces its assets. Unibail-Rodamco-Westfield is selling a building near Paris for €620 million. The SHIFT building, occupied by Nestlé France, was sold to French institutional investors. The sale is part of the Group's plan to generate €4 billion in sales by 2021.
The pace of the sale has been stepped up. Good news for Inventiva, which receives FDA "breakthrough therapy" status for lanifibranor in NASH. The US Drug Agency's "Breakthrough Therapy" program speeds up the administrative process for promising candidates in serious diseases.
Nestlé succeeds in its takeover bid for Aimmune. The group holds 84% of Aimmune's capital at the end of its takeover bid, which is therefore successful, not surprisingly. This acquisition allows Nestlé to diversify its offer in allergy treatments.
A breakthrough. Johnson & Johnson's clinical study on its Covid-19 vaccine is halted due to a patient becoming unexpectedly ill. This is a rather classic event in a clinical trial, but one that tends to provoke epidermal reactions in the current context. Faced with a similar concern recently, AstraZeneca was able to quickly resume its trial.
Mickey in streaming. The Walt Disney Company is reorganizing into three activities (studios, general entertainment and sports), served by a global distribution and marketing branch. Streaming becomes increasingly important for the group. The announcements pleased investors with a share price that rises sharply outside of the trading session.